Literature DB >> 17056311

Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.

Akiko Iida-Klein1, Shi Shou Lu, Felicia Cosman, Robert Lindsay, David W Dempster.   

Abstract

Previously, we demonstrated that the human parathyroid hormone (1-34) fragment (hPTH(1-34)) increased bone strength in proportion to its effects on BMD and cortical bone structure in the murine femur by comparing cyclic vs. daily administration of hPTH(1-34). Both cyclic and daily regimens increased vertebral BMD similarly at 7 weeks. Here, we have examined the effects of daily and cyclic PTH regimens on bone structure and cellular activity by static and dynamic histomorphometry. Twenty-week-old, intact female C57BL/J6 mice were treated with the following regimens (n=7 for each group): daily injection with vehicle for 7 weeks [control]; daily injection with hPTH(1-34) (40 microg/kg/day) for 7 weeks [daily PTH]; and daily injection with hPTH(1-34) (40 microg/kg/day) and vehicle alternating weekly for 7 weeks [cyclic PTH]. At days 9 and 10, and 2 and 3 prior to euthanasia, calcein (10 mg/kg) was injected subcutaneously. At the end of study, the lumbar vertebrae 1-3 and the left femora were excised, cleaned, and processed for histomorphometry. In the lumbar vertebrae, daily and cyclic PTH regimens significantly increased cancellous bone volume (BV/TV), trabecular number, trabecular osteoclast and osteoblast perimeters, trabecular mineral apposition rate (MAR) and bone formation rate (BFR), and periosteal MAR and BFR compared to control, with no significant difference between the two PTH-treated groups. Increased trabecular tunneling was observed in both PTH-treated groups. Both regimens tended to increase vertebral cortical bone formation parameters with the effects at the periosteum site being more marked than those at the endosteum site, resulting in a significant increase in cortical width. In the femur, the effects of cyclic PTH on BV/TV, trabecular width and number, trabecular and endocortical osteoblast and osteoclast perimeters, cortical width, and trabecular and periosteal BFR were less marked than those of daily PTH. A cyclic PTH regimen was as effective as a daily regimen in improving cancellous and cortical bone microarchitecture and cellular activity in the murine vertebra.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056311     DOI: 10.1016/j.bone.2006.09.010

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  14 in total

1.  RAGE supports parathyroid hormone-induced gains in femoral trabecular bone.

Authors:  Binu K Philip; Paul J Childress; Alexander G Robling; Aaron Heller; Peter P Nawroth; Angelika Bierhaus; Joseph P Bidwell
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-22       Impact factor: 4.310

2.  PTH Signaling During Exercise Contributes to Bone Adaptation.

Authors:  Joseph D Gardinier; Fatma Mohamed; David H Kohn
Journal:  J Bone Miner Res       Date:  2015-06       Impact factor: 6.741

3.  Dual-energy X-ray absorptiometry, peripheral quantitative computed tomography, and micro-computed tomography techniques are discordant for bone density and geometry measurements in the guinea pig.

Authors:  Ivy L Mak; Jason R DeGuire; Paula Lavery; Sherry Agellon; Hope A Weiler
Journal:  J Bone Miner Metab       Date:  2015-06-10       Impact factor: 2.626

4.  PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis.

Authors:  Fabio Vescini; Franco Grimaldi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

5.  Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact.

Authors:  Sebastien Elis; Hayden-William Courtland; Yingjie Wu; J Christopher Fritton; Hui Sun; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2010-09       Impact factor: 6.741

6.  Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts.

Authors:  Robert L Jilka; Charles A O'Brien; A Afshan Ali; Paula K Roberson; Robert S Weinstein; Stavros C Manolagas
Journal:  Bone       Date:  2008-10-22       Impact factor: 4.398

Review 7.  Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.

Authors:  Robert L Jilka
Journal:  Bone       Date:  2007-04-06       Impact factor: 4.398

8.  PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.

Authors:  Yumie Rhee; Matthew R Allen; Keith Condon; Virginia Lezcano; Ana C Ronda; Carlo Galli; Naomi Olivos; Giovanni Passeri; Charles A O'Brien; Nicoletta Bivi; Lilian I Plotkin; Teresita Bellido
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

9.  Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT.

Authors:  J E M Brouwers; B van Rietbergen; R Huiskes; K Ito
Journal:  Osteoporos Int       Date:  2009-03-05       Impact factor: 4.507

10.  Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.

Authors:  Zhiqiang Cheng; Wei Yao; Elizabeth A Zimmermann; Cheryl Busse; Robert O Ritchie; Nancy E Lane
Journal:  J Bone Miner Res       Date:  2009-02       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.